MDGL
Price
$544.51
Change
+$1.16 (+0.21%)
Updated
Jul 24 closing price
Capitalization
12.56B
17 days until earnings call
Intraday BUY SELL Signals
RPRX
Price
$58.83
Change
-$0.19 (-0.32%)
Updated
Jul 24 closing price
Capitalization
26.08B
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MDGL vs RPRX

MDGL vs RPRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MDGL vs. RPRX commentary
Jul 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and RPRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 25, 2026
Stock price -- (MDGL: $544.51 vs. RPRX: $58.83)
Brand notoriety: MDGL and RPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 20% vs. RPRX: 42%
Market capitalization -- MDGL: $12.56B vs. RPRX: $26.08B
MDGL [@Biotechnology] is valued at $12.56B. RPRX’s [@Biotechnology] market capitalization is $26.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileRPRX’s FA Score has 2 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • RPRX’s FA Score: 2 green, 3 red.
According to our system of comparison, RPRX is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 5 TA indicator(s) are bullish while RPRX’s TA Score has 4 bullish TA indicator(s).

  • MDGL’s TA Score: 5 bullish, 5 bearish.
  • RPRX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, RPRX is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а -1.62% price change this week, while RPRX (@Biotechnology) price change was +1.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.

Reported Earning Dates

MDGL is expected to report earnings on Aug 11, 2026.

RPRX is expected to report earnings on Aug 12, 2026.

Industries' Descriptions

@Biotechnology (-4.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RPRX($26.1B) has a higher market cap than MDGL($12.6B). RPRX YTD gains are higher at: 53.725 vs. MDGL (-6.496). RPRX has higher annual earnings (EBITDA): 1.7B vs. MDGL (-281.09M). RPRX has more cash in the bank: 1.39B vs. MDGL (813M). MDGL has less debt than RPRX: MDGL (347M) vs RPRX (8.96B). RPRX has higher revenues than MDGL: RPRX (2.44B) vs MDGL (1.13B).
MDGLRPRXMDGL / RPRX
Capitalization12.6B26.1B48%
EBITDA-281.09M1.7B-17%
Gain YTD-6.49653.725-12%
P/E RatioN/A30.96-
Revenue1.13B2.44B46%
Total Cash813M1.39B59%
Total Debt347M8.96B4%
FUNDAMENTALS RATINGS
MDGL vs RPRX: Fundamental Ratings
MDGL
RPRX
OUTLOOK RATING
1..100
5577
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
1
Undervalued
PROFIT vs RISK RATING
1..100
1841
SMR RATING
1..100
9988
PRICE GROWTH RATING
1..100
4038
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RPRX's Valuation (1) in the Pharmaceuticals Major industry is significantly better than the same rating for MDGL (70) in the Pharmaceuticals Other industry. This means that RPRX’s stock grew significantly faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (18) in the Pharmaceuticals Other industry is in the same range as RPRX (41) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to RPRX’s over the last 12 months.

RPRX's SMR Rating (88) in the Pharmaceuticals Major industry is in the same range as MDGL (99) in the Pharmaceuticals Other industry. This means that RPRX’s stock grew similarly to MDGL’s over the last 12 months.

RPRX's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as MDGL (40) in the Pharmaceuticals Other industry. This means that RPRX’s stock grew similarly to MDGL’s over the last 12 months.

RPRX's P/E Growth Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that RPRX’s stock grew significantly faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLRPRX
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
52%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
49%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
55%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
58%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 3 days ago
55%
Declines
ODDS (%)
Bearish Trend 13 days ago
80%
Bearish Trend 6 days ago
51%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
53%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signal:
Gain/Loss:
RPRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BVS11.800.32
+2.79%
Bioventus
IPAR122.552.80
+2.34%
Interparfums Inc
TRAK8.150.13
+1.62%
ReposiTrak
CFG71.880.08
+0.11%
Citizens Financial Group
MTEX4.97-0.08
-1.58%
Mannatech

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
-0.32%
AXON - RPRX
48%
Loosely correlated
+2.12%
INCY - RPRX
37%
Loosely correlated
+0.84%
REGN - RPRX
34%
Loosely correlated
+0.63%
HALO - RPRX
33%
Loosely correlated
+1.35%
MDGL - RPRX
31%
Poorly correlated
+0.21%
More